Veradigm Inc. (NASDAQ:MDRX) Shares Sold by Putnam Investments LLC

Putnam Investments LLC trimmed its stake in shares of Veradigm Inc. (NASDAQ:MDRX – Get Rating) by 6.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 123,037 shares of the software maker’s stock after selling 9,187 shares during the quarter. Putnam Investments LLC owned about 0.11% of Veradigm worth $1,874,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in MDRX. Bank of New York Mellon Corp raised its position in shares of Veradigm by 3.1% during the 1st quarter. Bank of New York Mellon Corp now owns 1,323,414 shares of the software maker’s stock worth $29,803,000 after purchasing an additional 39,210 shares during the period. Citigroup Inc. raised its position in shares of Veradigm by 1.8% during the 1st quarter. Citigroup Inc. now owns 118,927 shares of the software maker’s stock worth $2,678,000 after purchasing an additional 2,157 shares during the period. Natixis Advisors L.P. raised its position in shares of Veradigm by 23.8% during the 1st quarter. Natixis Advisors L.P. now owns 86,478 shares of the software maker’s stock worth $1,948,000 after purchasing an additional 16,642 shares during the period. Bank of Montreal Can raised its position in shares of Veradigm by 3.6% during the 1st quarter. Bank of Montreal Can now owns 34,210 shares of the software maker’s stock worth $768,000 after purchasing an additional 1,198 shares during the period. Finally, MetLife Investment Management LLC raised its position in shares of Veradigm by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 68,294 shares of the software maker’s stock worth $1,538,000 after purchasing an additional 24,794 shares during the period. 99.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on MDRX shares. SVB Securities dropped their price target on Veradigm from $24.00 to $17.00 in a research report on Wednesday, March 1st. Argus upgraded Veradigm from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research report on Wednesday, December 7th. They noted that the move was a valuation call. TheStreet upgraded Veradigm from a “c+” rating to a “b-” rating in a research report on Wednesday, November 30th. JPMorgan Chase & Co. raised their target price on Veradigm from $19.00 to $20.00 and gave the company an “underweight” rating in a research report on Friday, November 18th. Finally, Piper Sandler cut Veradigm from an “overweight” rating to a “neutral” rating and raised their target price for the company from $17.00 to $18.50 in a research report on Wednesday, February 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $20.90.

Veradigm Stock Down 2.2 %

Shares of MDRX stock opened at $13.88 on Monday. Veradigm Inc. has a 1 year low of $13.59 and a 1 year high of $23.25. The stock has a market cap of $1.52 billion, a PE ratio of 32.28, a price-to-earnings-growth ratio of 1.28 and a beta of 1.01. The business’s fifty day moving average is $17.22 and its 200-day moving average is $16.91. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.20 and a current ratio of 3.20.

About Veradigm

(Get Rating)

Veradigm, Inc engages in the provision of clinical, financial, and operational results services. It operates through the Provider and Veradigm segments. The Provider segment includes the hospitals and health systems, ambulatory, CarePort, FollowMyHealth, EPSiTM, EISClassics, and 2bPrecise strategic business units.